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Abstract
Background: Copper has antimicrobial properties and has been studied for its activity against viruses, including
HIV. Copper complexed within a phthalocyanine ring, forming copper (II) phthalocyanine sulfate (CuPcS), may have
a role in microbicide development when used intravaginally.
Methods: CuPcS toxicity was tested against cervical epithelial cells, TZM-BL cells, peripheral blood mononuclear
cells (PBMC), and cervical explant tissues using cell viability assays. In vivo toxicity was assessed following
intravaginal administration of CuPcS in female BALB/C mice and measured using a standardized histology grading
system on reproductive tract tissues. Efficacy studies for preventing infection with HIV in the presence of various
non-toxic concentrations of CuPcS were carried out in TZM-BL, PBMC, and cervical explant cultures using HIV-1BAL
and various pseudovirus subtypes. Non-linear regression was applied to the data to determine the EC50/90 and
CC50/90.
Results: CuPcS demonstrated inhibition of HIV infection in PBMCs at concentrations that were non-toxic in cervical
epithelial cells and PBMCs with EC50 values of approximately 50 μg/mL. Reproductive tract tissue analysis revealed
no toxicity at 100 mg/mL. Human cervical explant tissues challenged with HIV in the presence of CuPcS also
revealed a dose–response effect at preventing HIV infection at non-toxic concentrations with an EC50 value of
65 μg/mL.
Conclusion: These results suggest that CuPcS may be useful as a topical microbicide in concentrations that can be
achieved in the female genital tract.
Background
The need for an effective microbicide to prevent sexual
transmission of HIV is a well-understood holy grail in
prevention efforts. Beyond effectiveness, other important
features of a microbicide include ease of application
intravaginally and intrarectally, acceptable product char-
acteristics, affordability, safety with repeated use, thermal
and pH stability, and long-lasting effect. A successful mi-
crobicide should not disrupt the vaginal flora or mucosal
epithelium or alter the pH, which may predispose to
additional infections [1]. Other features of more debat-
able value include non-coital dependence and opportun-
ity for covert use. A microbicide that could dually
protect against other sexually transmitted infections or
prevent pregnancy may be especially desirable as these
conditions increase risk of HIV transmission [2–4].
Copper has known bactericidal, fungicidal, and viru-
cidal properties [5–7]. In vitro, copper-based compounds
have been shown to prevent HIV infection through sev-
eral mechanisms: irreversible inactivation of the essential
HIV-1 enzyme protease [8], induction of free radical
damage to nucleic acids [9], prevention of p24 produc-
tion and syncytia formation in HIV-infected cells [9], in-
hibition of gp120 binding [10, 11], and prevention of
viral fusion [11].
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Most copper-induced insults to cells are the result of
free radical damage to biomolecules [7], which can be
countered by eukaryotic cells through mechanisms that
sequester, expel, or inactivate the copper ions or effi-
ciently repair the damage [12]. Free copper ions diffus-
ing throughout the vagina have the potential to produce
reactive species that could damage the integrity of the
vaginal epithelial cell barrier by overwhelming cell repair
mechanisms or by interfering with protective microflora
[5]. However, copper ions complexed within larger mole-
cules such as sulfonated phthalocyanines (CuPcS) might
prevent the production of such reactive species while
also precluding absorption across the epithelial barrier
and intracellular penetration.
Previous studies have demonstrated that CuPcS both
protects against HIV infection of human T cells and
elicits HIV inactivation in vitro [9, 11, 13–15]. It has also
been shown to be non-toxic against Lactobacillus spp.,
the primary protective vaginal bacteria [14]. Addition-
ally, it prevents cell-associated virus transmission and
demonstrates effectiveness in preventing HIV transmis-
sion in general throughout a broad pH range, as occurs
in the vagina [14]. Although the copper and phthalo-
cyanine groups account for most of the HIV-preventing
activity, the sulfate groups may afford additional protec-
tion against HIV infection by blocking both the endocy-
tic and receptor-mediated pathways that HIV can utilize
to infect cells [16, 17]. The mechanisms by which CuPcS
is known to prevent HIV infection include interference
with viral envelope attachment to cell receptors and in-
hibition of viral entry into cells [14]. In a similar way,
copper-impregnated filters have been tested in clinical
trials to inactivate HIV in breast milk of HIV-positive
mothers [15].
This study examines the feasibility of using CuPcS as a
novel microbicide. CuPcS has not previously been stud-
ied in vivo. Using the established approach for preclin-
ical development of microbicides, the product was tested
for toxicity against epithelial cells as well as efficacy in
peripheral blood mononuclear cells and TZM-BL cells.
Mice and cervical explants provided models for toxicity
and efficacy, respectively.
Results and discussion
Toxicity in cell cultures. Nontoxic concentrations of
CuPcS were determined by exposing ME-180, TZM-BL,
and PBMC cell lines to various concentrations of the
compound. CC50 values were determined by applying
non-linear regression to the data (Fig. 1). The ME-180
and TZM-BL cell lines demonstrated similar levels of
toxicity with CC50s of 662.6 μg/mL and 543 μg/mL, re-
spectively. The CC50 of PBMCs could not be deter-
mined as this level of toxicity was never observed. Visual
inspection of epithelial cell lines using a light microscope
demonstrated slight disruption of epithelial layer integrity
at concentrations of 1000 and 2000 μg/mL.
Antiviral activity in TZM-BL cells. Antiviral activity of
CuPcS in TZM-BL cells was determined by pre-treating
pseudoviruses with varying nontoxic concentrations of
CuPcS and then incubating with TZM-BL cells. A dose–
response effect was observed with increasing concentra-
tions of CuPcS (Fig. 2). Non-linear regression models
were used to determine EC50 and EC90 values (Table 1).
Results were within one order of magnitude across the
various pseudovirus strains.
Antiviral activity in PBMCs. PBMCs were combined
with HIV-1BAL and nontoxic concentrations of CuPcS. A
dose–response effect was observed with increasing
Fig. 1 CuPcS Toxicity in Cervical Epithelial Cells and PBMCs. Copper
phthalocyanine sulfate (CuPcS) was combined with two cervical
epithelial cell lines (ME-180 and TZM-BL) and peripheral blood
mononuclear cells (PBMC) at increasing concentrations in quadruplicate.
Toxicity was measured as percent viable cells determined by MTT assay
or trypan blue exclusion with epithelial cells or PBMCs, respectively, after
48 h of incubation with CuPcS. A dose response effect is observed with
increasing concentrations. CC50 values: TZM-BL = 973.7,
and ME-180 = 662.6
Fig. 2 Effect of CuPcS on Pseudovirus Infection of TZM-BL Cells.
Copper phtahlocyanine sulfate (CuPcS) was combined with nine
different Subtype B, HIV-1 pseudoviruses for one hour prior to
addition of TZM-BL cells. Level of infectivity was determined by
using a p24 assay performed in triplicate and was observed to have
dose–response effect
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concentration (Fig. 3). Non-linear regression models
were used to calculate EC50 and EC90 (Table 2). Values
were similar regardless of the order of combination ex-
cept when HIV was pre-treated with 100 μg/mL CuPcS
and then combined with PBMCs and additional CuPcS,
which was designed to assess irreversible virucidal activ-
ity of the compound. Pre-treatment of virus resulted in
nearly complete inhibition regardless of post-treatment
concentration.
Toxicity in mice. Of the 39 mice evaluated histologi-
cally, one of the Group 1 (N = 3) control mice, was elim-
inated due to the presence of bilateral, granulosa cell
tumors in the ovary. For the remaining 38 animals,
Group 2 (N = 12) 1 % Carbopol gel, Group 3 (N = 12)
10 mg/ml CuPcS in 2 % Carbopol gel, and Group 4 (N =
12) 100 mg/ml CuPcS in 2 % Carbopol gel, standard histo-
logic guidelines were used to determine the stage of
estrous prior to evaluating the average number and type
of leukocytes in the lamina propria of the uterus and va-
gina (Additional file 1: Table S1). In the diestrus phase, on
average, there were small and small-medium numbers of
leukocytes in the lamina propria of the vagina in Groups 3
and 4 (10 mg/ml and 100 mg/ml CuPcS, respectively), and
small, small-medium, and medium numbers of leukocytes
in the lamina propria of the vagina in Groups 1 and 2 (no
CuPcS) (Additional file 2: Table S2). In the proestrus
phase, on average, there were occasional, small, and small-
medium numbers of leukocytes in the lamina propria of
the vagina in Groups 3 and 4 (10 mg/ml and 100 mg/ml
CuPcS, respectively), and small and small-medium num-
bers of leukocytes in the lamina propria of the vagina in
Groups 1 and 2 (no CuPcS) (Additional file 3: Table S3).
Sample histology photos are demonstrated in Fig. 4. The
results strongly suggest that there is no significant dif-
ference within or between treatment groups, when seg-
regated by estrous phase, in the level of leukocytic
infiltration in the lamina propria of the vagina or uterus
when comparing animals treated with 10 mg/ml and
100 mg/ml CuPcS to animals treated with 1 % Carbopol
gel alone or with no intervention. However, further
studies are needed with larger numbers of animals in
each estrous phase to definitively document a lack of
statistical significance.
Toxicity in cervical explant tissues. Cervical explant
tissues were assayed for toxic effects of CuPcS using a
MTT assay. Because the study was performed on tissues
previously infected with HIV after exposure to CuPcS,
Table 1 The EC50 and EC90 values for copper phthalocyanine
sulfate (CuPcS) preventing HIV-1 pseudovirus infection of TZM-BL
cells were determined with a nonlinear regression model and was
comparable across pseudovirus subtypes
Efficacy for pre-treatment of HIV with CuPcS










Fig. 3 Effect of CuPcS on HIV Infection of PBMCs. A dose–response
effect was observed for the prevention of HIV-1BAL infection in
peripheral blood mononuclear cells (PBMC) with increasing
concentrations of copper phthalocyanine sulfate (CuPcS) under
different orders of combination in triplicate
Table 2 The concentrations at which 50 and 90 % of infections
are prevented under the various conditions of copper
phthalocyanine sulfate (CuPcS) exposure: HIV pre-treated with
CuPcS; peripheral blood mononuclear cells (PBMC) pre-treated
with CuPcS; simultaneous addition of HIV, PBMCs, and CuPcS;
and pre-incubation of HIV and PBMCs with subsequent addition
of CuPcS
CuPcS Inhibition of HIV-1BAL Infection of PBMCs
EC50 μg/ml EC90 μg/ml
HIV pre-treated 53.31 184.7
PBMCs pre-treated 42.96 147.2
CuPcS added post-infection 26.11 215.3
Combined addition 54.72 186.7
Pre (100 μg/mL)- and post-treatment Undefined Undefined
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the assay was intended to provide a qualitative assess-
ment of toxicity. The OD/mg tissue remained above the
50 % level. There was no observed loss of tissue viability
over the seven days of exposure with increasing concen-
trations of CuPcS (Additional file 4: Table S4).
Antiviral activity in cervical explant tissues. Cervical tis-
sue was incubated with CuPcS suspended in cell medium
for three hours before the addition of HIV-1BAL and tested
for infection at days 3, 5, and 7 with continued exposure
to CuPcS. Data from days 5 and 7 were combined as these
results were unlikely to contain residual inoculum and
would represent cumulative p24 production since the
supernatant was changed after each sampling. Using a
non-linear regression model, the EC50 for the combined
data on days 5 and 7 was determined to be 65.46 μg/mL,
and the EC90 was 118.3 μg/mL. Percent inhibition was
calculated based on reduction in p24 concentration com-
pared to controls. Statistically significant inhibition of HIV
infection was observed for increasing concentrations of
CuPcS above 50 μg/mL (p < 0.05) (Fig. 5).
The results of the cell-based toxicity experiments re-
veal CC50 values comparable to other studies with
values consistently greater than 500 μg/mL [11, 14]. The
in vitro EC50 values are within a log of previously re-
ported values [10, 11, 14]. Reasons for the variability in
efficacy may include differences in product purity and
preparation, various HIV or pseudo-virus strains tested,
and laboratory equipment calibration. This is the first
published study to have investigated CuPcS in ex vivo
and in vivo models. Previous pre-clinical studies that
have shown promise for further development may not
have been pursued given an increased focus by re-
searchers and funders on developing microbicides based
on known anti-retroviral therapies.
A long-acting microbicide would have sustained con-
tact with the epithelium, potentiating the opportunity
Fig. 4 Murine Reproductive Tract Tissue after CuPcS Exposure. The images are cross sections of vaginal tissue samples stained with H&E from
mice in various stages of estrus. a Mid-vagina: diestrus, Group 2 (1 % Carbopol gel). The stratum germantivum is thickening and the epithelial cells
in the superficial layers are demonstrating early mucification. Multifocally, occasional leukocytes are present in the superficial epithelial cell layers
and small to small-medium numbers of leukocytes are present in the lamina propria. H&E, 40X. b Mid-vagina: diestrus, Group 4 (100 mg/ml
CuPcS). The stratum germantivum is thickening and the epithelial cells in the superficial layers are consistent with early mucification. Multifocally,
occasional to small numbers of leukocytes are present in the superficial epithelial cell layers and occasional to small-medium numbers of
leukocytes are present in the lamina propria. H&E, 40X. c Mid-vagina: proestrus, Group 2 (1 % Carbopol gel). The outer stratum mucification layer
is composed of epithelial cells containing mucin vacuoles and overlies a thin, eosinophilic stratum corneum. There is an absence of leukocytes in
the underlying stratum granulosum and stratum germintivum. Occasional to small numbers of leukocytes are present in the lamina propria. H&E,
40X. d Mid-vagina: proestrus, Group 4 (100 mg/ml CuPcS). The outer stratum mucification layer is composed of epithelial cells containing mucin
vacuoles and overlies an eosinophilic-staining stratum corneum showing artifactual intra-layer separation of the cornified cells. There is an
absence of leukocytes in the underlying stratum granulosum and stratum germintivum. Occasional leukocytes are present in the lamina propria.
H&E, 40X. e Mid-vagina: diestrus, Group 1 (Control). The stratum germantivum is thickening and the epithelial cells in the superficial layers are
becoming polyhedral in shape. Multifocally, small to small-medium numbers of degenerate leukocytes are present in the superficial epithelial cell
layers and occasional to small numbers of leukocytes are present in the lamina propria. H&E, 40X
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for toxic effects to be seen. This study addresses this
issue by extending the time of incubation of CuPcS with
cell lines to 48 h, observing toxicity to cervical explants
over seven days, and exposing mice to daily CuPcS ad-
ministration for one week. Notably, the lack of observed
toxicity occurred despite pre-treating the mice with
medroxyprogesterone to enhance their susceptibility to
toxic effects by thinning the epithelium.
Toxicity was observed at increased concentrations in
the epithelial cell lines, though no gross toxicity was
seen at any concentration in mice. This difference may
be attributable to the inherent biological protective fac-
tors of the vaginal mucosal environment such as a circu-
lating immune response and interplay of vaginal
secretions and microflora [18], or it may be a limitation
of the study design itself. It is unclear how the in vitro
therapeutic index of approximately 100 would translate
in vivo as no significant toxicity was seen in non-
polarized cervical explants or at concentrations up to
100 mg/mL in the mouse model. However, it should be
noted that mouse models are an imperfect representa-
tion of the human female genital tract, and further stud-
ies using rabbit vaginal irritation models and primates
should be performed to better address this issue before
carrying out human studies.
Different methods were used to determine the results
(MTT assay versus trypan blue exclusion) because the
MTT assay requires the addition and removal of solu-
tions at several steps along with subsequent washings to
remove the highly pigmented CuPcS that might interfere
with the assay. Without adherence of the PBMCs, too
many cells were lost to obtain an accurate reading of
viability by spectrophotometry. Trypan blue exclusion is
often considered an inexact method of assessing viabil-
ity. However, other studies have demonstrated equivalent
results between MTT assays and trypan blue exclusion
[18]. Similarly, the results in the present study were
comparable among the cell lines regardless of the
method used. Though the compound has a prominent
blue color at high concentrations, it did not interfere
with the MTT assay in controls after adding additional
wash steps. One limitation of the data is the assessment
of the epithelial integrity. Future studies should include
measurements of transepithelial electrical resistance as a
means of quantifying epithelial disruption, in particular,
because previous sulfate-based microbicides have dem-
onstrated clinical failure as a result of epithelial com-
promise [19].
A microbicide must also be non-immunogenic in the
reproductive tract as immunologic responses to microbi-
cide exposure may recruit more inflammatory cells to
the mucosal epithelium, which would provide a larger
number of permissive cells at the epithelial barrier at
risk of infection [20]. This study showed no increase in
the number of leukocytes observed over controls in the
reproductive tract tissues of mice.
Susceptible CD4 cells in subcutaneous tissue are consid-
ered an important component of transmitting HIV across
the epithelial barrier to the blood stream and are primary
targets for HIV infection [21]. Thus, preventing infection
of these crucial carriers may significantly reduce HIV ac-
quisition. In this study, efficacy in preventing infection of
PBMCs produced an expected dose–response effect of
CuPcS. With one exception, viral concentrations on day 5
and 6 under the various conditions were nearly equivalent
indicating that the order of exposure is not critical. Thus,
there may be multiple mechanisms by which CuPcS
inhibits HIV infection. The scenario with pre- and post-
treatment of HIV resulted in consistent inhibition regard-
less of the concentration added in the post-treatment step.
This may represent irreversible inactivation of the virus by
CuPcS because no viral activity returned following re-
moval of the initial compound. Because the preincubation
of PBMCs and HIV for one hour prior to CuPcS demon-
strated dose–response inhibition, CuPcS may also be act-
ing at a later stage in the viral life cycle. The CuPcS is not
anticipated to have interfered with the p24 assay or the
viability of the cells because incubation of PBMCs with
CuPcS followed by triple washing and the addition of an
HIV standard produced the same results as adding that
standard to PBMCs alone.
Conclusions
In this study we demonstrate that CuPcS has activity
against HIV-1 in the range of concentrations that are
nontoxic to cervical epithelial cells, PBMCs, and cervical
Fig. 5 Inhibition of HIV Infection in Cervical Explants. The increasing
effectiveness of copper phthalocyanine sulfate (CuPcS) at preventing
HIV-1BAL infection of cervical explants with increasing concentrations
of CuPcS is presented with standard error bars. Tissues were tested
in sets of 4 or 8 at each concentration. Asterisks denote statistically
significant differences in inhibition between concentrations of CuPcS
using a one-way ANOVA test (p < 0.05)
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explant tissues. Likewise, CuPcS has a broad safety range
in cervical explants and the genital tract of mice. This
study enhances previous findings by replicating in vitro
data and expanding to include both in vivo and ex vivo
models [8–11, 13–15]. While these data represent pre-
liminary investigations, the results are promising, and
CuPcS should be considered for further evaluation as a
potential topical microbicide against HIV.
Useful areas of potential investigation to expand the
scope of this study could include the following: measuring
effects using other virus clades and cell lines; evaluating
for cell-associated virus transmission to see how CuPcS af-
fects the transfer of virus from dendritic cells to PBMCs;
conducting more sensitive tests of proinflammatory
effects; and performing assays for altered susceptibility, in-
cluding intrarectally, to subsequent viral challenge in ani-
mal models to demonstrate toxicity.
The field of HIV treatment has long battled against
the rapid rise in drug resistance. Increasing access to
pharmaceuticals in the global population has resulted in
greatly expanded life expectancy for those who have
been infected with HIV. However, the inconsistent sup-
ply of medications coupled with the challenge of adher-
ence to a lifetime of daily drug therapy has caused an
increase in primary acquisition and superinfection with
resistant viruses worldwide [22–28]. Though partial effi-
cacy to many of the first-line drugs remains, this may
pose a mounting challenge to prevention efforts. Thus, it
is critical for the field to diversify its prevention portfo-
lios to include innovations such as the one presented
here that may interfere at several points of HIV infection
and transmission. Furthermore, until there is a preven-
tion modality that meets all the complex needs and
demands of the population at risk, researchers and fun-




PBMCs were obtained through phlebotomy with consent
from healthy, HIV-negative volunteers in accordance
with a protocol approved by the Institutional Review
Board at the University of Illinois at Chicago (Protocol
number: 2009–0737). Ectocervical tissue was obtained
with consent from women undergoing hysterectomies
for benign disease under a protocol approved by the
Institutional Review Board at Rush University Medical
Center, Chicago, IL. All research with mice conformed
to the Animal Care Policy set forth by the University of
Illinois at Chicago Animal Care Committee, which is
accredited by the Association for Assessment and Ac-
creditation of Laboratory Animal Care – International,
and in accordance with the Guide for the Care and Use
of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Office of Ani-
mal Care and Institutional Biosafety Committee at the
University of Illinois at Chicago (Permit Number:
201101675). Measures to minimize suffering during tox-
icity studies in the mice included daily observation for
signs of mucocutaneous irritation, weight loss, or other
evidence of distress, which would be indications to re-
move the animals from further participation in the study.
All animal handlers were trained by the veterinarian of the
Animal Care Committee in the careful handing of the ani-
mals during administration of the microbicide to place
light traction on the back while elevating the hind legs
using the tail. Microbicide was administered quickly and
gently using new, sterilized, intact pipettes in under five
seconds per mouse, minimizing total handling time. This
process was determined to be a non-painful and minim-
ally distressing means of microbicide administration by
the veterinarian of the Animal Care Committee. Mice
were sacrificed using CO2 narcosis, which is considered a
humane and acceptable method of euthanasia through its
painless induction of somnolence.
Test compound
Copper(II) phthalocyanine-tetrasulfonic acid tetraso-
dium salt (CuPcS) (molecular weight 988.28) was ob-
tained from Sigma-Aldrich (St. Louis, MO). Stock
solutions were created using PBS with a pH of 7.2 at a
concentration of 100 μg/mL. This was used for all stud-
ies on cell and tissue cultures.
Cells
Human cervical ME-180 epithelial cells were obtained
from ATCC (Manassas, VA, lot no. 57758662) and main-
tained in McCoy’s 5a medium supplemented with 10 %
heat-inactivated fetal bovine serum, 1 % L-glutamine,
100 U/mL penicillin, and 100 μg/mL streptomycin. The
TZM-BL cell line, an engineered He-La cervical cell line
that expresses CD4, CXCR4, and CCR5 and contains
Tat-inducible Luc and ß-Gal reporter genes, was ob-
tained through the NIH AIDS Reagent Program, NIAID,
NIH: TZM-BL from Dr. John C. Kappes, Dr. Xiaoyun
Wu and Tranzyme Inc. [29], and maintained in Dulbec-
co’s Modified Eagle Medium (DMEM) supplemented as
above with 1 % sodium pyruvate. PBMCs were isolated
using gradient-density centrifugation. The cells were cul-
tivated in complete RPMI medium supplemented as with
DMEM for three days and stimulated with 10 μg/mL
phytohemagglutinin (PHA) and 10 % rIL-2 (obtained
through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: Human rIL-2 from Dr. Maurice
Gately, Hoffmann - La Roche Inc. [30]). PBMCs were then
washed and suspended in complete RPMI with 10 % IL-2.
All cells were maintained at 37 °C in 5 % CO2.
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HIV-1 stocks
The HIV-1BAL, a CCR5 tropic virus, was obtained through
the NIH AIDS Reagent Program, NIAID, NIH: HIV-1BAL
from Drs. Suzanne Gartner, Mikulas Popovic, and Robert
Gallo [31]. Stocks were created by combining the virus with
PHA-stimulated PBMCs, adding IL-2, and collecting super-
natant at days 5 and 7. Viral concentrations were deter-
mined using the p24 Antigen Capture Assay Kit provided
by the National Cancer Institute (NIH, Bethesda, MD).
Pseudovirus preparation
The Standard Reference Panel of Subtype B HIV-1 Env
clones was obtained through the AIDS Reagent Program,
NIAID, NIH from the following contributors: QH0692
clone 42 (SVPB6), PVO clone 4 (SVPB11), TRO clone 11
(SVPB12), AC10.0 clone 29 (SVPB13) and SC422661
clone B (SVPB8) from Drs. David Montefiori and Feng
Gao; pREJO4541 clone 67 (SVPB16), pRHPA4259 clone 7
(SVPB14) from Drs. B.H. Hahn and J.F. Salazar-
Gonzalez; pTHRO4156 clone 18 (SVPB15) and
pCAAN5342 clone A2 (SVPB19) from Drs. B.H. Hahn
and D.L. Kothe [32–34]. The env expression vector pNL4-
3.Luc.R-.E- was also obtained through the same NIH
AIDS Reagent Program from Dr. Nathaniel Landau.
Stocks of single-round-infection HIV-1 Env pseudo-
virus were produced by cotransfecting 293 T cell mono-
layers at 70 % confluency in 6-well plates with 3 μg
pNL4-3.Luc.R-.E- and 0.5–4.0 μg env clone plasmid with
the transfection reagent polyethylenimine. Pseudovirus
stocks were harvested 48 h post-transfection and filtered
with a 0.45-μm filter. To test infectivity, TZM-BL cells
were inoculated with each of the stocks. Infectivity was
determined after 72 h by measurement of chemilumines-
cence produced by at least a 5-fold increase in luciferase
activity relative to the background chemiluminescence
of the vector alone. Stock aliquots were stored at −80 °C
until use.
Toxicity in cell culture
Fifty thousand ME-180 or TZM-BL cells were added to
each well of a 96-well plate and incubated for 24 h.
CuPcS dissolved in PBS was added to the wells with cul-
ture medium in quadruplicate to produce final concen-
trations of 0–2000 μg/mL CuPcS. Cells were incubated
with CuPcS for 48 h at 37 °C and then washed with fresh
medium. MTT (3–(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) Cell Proliferation Assay Kit was
obtained from Cayman Chemical (Ann Arbor, MI; lot
no. 0417667), and the MTT reagent was added to each
well and incubated for 3½ hours. Cells were manually
washed with Hank’s balanced salt solution before
crystal-dissolving solution was added. The plate was in-
cubated at room temperature in dark conditions for
90 min. Cells were examined using a light microscope
for preserved confluence and adherence. Viability was
determined through light absorbances read by Vmax
Kinetic Microplate Reader (Molecular Devices Corpor-
ation, Sunnyvale, CA) at 562 nm. Because of the non-
adherence of PBMCs and subsequent difficulty washing
out the residual pigmented CuPcS, toxicity in PBMCs
was estimated with trypan blue exclusion.
Antiviral activity in TZM-BL cells
TZM-BL cells were seeded in 96-well plates (5 × 103
cells per well) and incubated at 37 °C in a 5 % CO2 at-
mosphere for 24 h. CuPcS was diluted serially with
DMEM and incubated in triplicate with pseudoviruses
SVPB6, SVPB11, SVPB12, SVPB13, SVPB16, SVPB14,
SVPB15, SVPB19, and SVPB8 (at dilutions equivalent to
a 5–15 fold increase in luminescence over background)
at 37 °C for 1 h. The mixture was added to TZM-BL
cells (100 μL/well), and the plates were further incubated
at 37 °C for an additional hour. Then 100 μL DEAE Dex-
tran was added to each well, and the plates were incubated
at 37 °C for 48 h. Cells were lysed by adding 100 μL Lucif-
erase Cell Culture Lysis 5x Reagent (Promega, Madison,
WI) to each of the wells. Cell extracts were measured
for luminescence using Monolight 3010 Luminometer
(Pharmingen, San Diego, CA).
Antiviral activity in PBMCs
HIV-1BAL was grown in PBMCs as described above.
Antiviral activity of CuPcS was determined using p24
ELISA. CuPcS was combined with 1,225 pg virus (mea-
sured as p24) and 15,000 PBMCs in 96-well plates under
various conditions in triplicate: 1) PBMCs were infected
with HIV for one hour, then incubated with CuPcS for
two hours; 2) virus was pre-treated with CuPcS for one
hour before adding PBMCs with or without additional
CuPcS; 3) PBMCs were pre-treated with CuPcS for one
hour before the addition of virus; and 4) PBMCs, virus,
and CuPcS were simultaneously combined. In all condi-
tions, PBMCs were subsequently washed to remove
compound and residual virus, and new medium was
added. Supernatant was collected on days 4–6 and tested
for viral replication. To quantify virus present, p24 concen-
trations were determined and used to calculate inhibition
as percent reduction in p24 concentrations compared with
controls.
Product development
A common polymer used as a microbicide matrix is
Carbopol®. Carbopol 940 was selected because of its abil-
ity to sustain the viscosity of a thick gel over a broad
range of alterations in temperature and pH to aid in re-
tention within the vagina. However, to offset the partial
reduction in viscosity posed by increasing concentrations
of CuPcS, higher percentages of Carbopol were used for
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higher concentrations of CuPcS. The final formulations
ranged from 1.5–3 % Carbopol with 250 μg/mL –
100 mg/mL CuPcS. These compounds were used exclu-
sively for the studies of toxicity in mice. The compound
was neutralized with triethanolamine to a pH around 7.
Toxicity in mice
Six- to ten-week old female BALB/C mice were obtained
from Charles River Laboratories (Frederick, MD). The
mice received subcutaneous injections of 3 mg medroxy-
progesterone acetate (Greenstone LLC, Peapack, NJ) five
days prior to microbicide application. The purpose of
the medroxyprogesterone in this study was to mimic the
luteal phase of the menstrual cycle by thinning the epi-
thelial lining, thus rendering it more susceptible to po-
tential irritants. Mice received daily intra-vaginal
applications of 40 μL of CuPcS in Carbopol using 50-μL
Wiretrol glass pipettes (Drummond-Scientific, Broomall,
PA) over seven days. Pipettes were manipulated in and
out five times to ensure distribution of the microbicide
throughout the vagina. Mice were examined daily for
signs of genital irritation and then sacrificed with CO2
narcosis at 1, 2, or 3 weeks post-microbicide application.
Female mouse reproductive tracts were harvested and
fixed in 10 % neural buffered formalin for 8–12 h, washed
with phosphate buffer solution and stored in 70 % ethanol
prior to processing. Sections of ovary, uterus, cervix and
vagina were exposed to routine processing, embedded in
paraffin and sectioned at 5 microns. Tissue sections were
stained with hematoxylin and eosin and evaluated by a
veterinary pathologist. Due to the variability of leukocytic
infiltrates in the rodent uterus and vagina during the es-
trous cycle, standard histologic guidelines were used to
determine the stage of estrous for each animal [35]. A 7
tier numerical grading scale, i.e., grades 1–7: 1 = occa-
sional (0–3 cells per hpf), 2 = small (4–10 per hpf), 3 =
small-medium (11–20 per hpf), 4 =medium (21–30 per
hpf), 5 =medium-large (31–40 per hpf), 6 = large (41–50
per hpf) and 7 =marked (>50 per hpf), was used to evalu-
ate the average number of leukocytes in the lamina pro-
pria of the uterus and vagina. In randomly selected sites,
the number of leukocytes observed in 4–6 fields, were
counted at 400X magnification. The numerical field values
were then averaged and recorded as a range for within
and between group comparisons.
Antiviral activity in cervical explant tissues
Single, non-polarized pieces of ectocervical tissue ap-
proximately 3 mm3 in size were placed in inner wells of
48-well culture plates [36]. CuPcS stock solution was di-
luted using RAFT medium (DMEM containing 24 %
Ham’s F-12 medium, 4 mg/mL insulin, 100 Units/mL
Pen/Strep, 50 μg/mL gentamicin, 10 % FBS, and 20 mM
HEPES buffer). Tissues were incubated with each of the
CuPcS concentrations for three hours before inoculation
with HIV-1BAL stock at 5,880 TCID50. For each condi-
tion there were 4 to 8 tissue replicates. Three days fol-
lowing inoculation, tissues were washed twice with
RPMI and transferred to a 48-well plate with fresh
medium containing appropriate concentrations of
CuPcS. Supernatant was removed five hours after the
initial wash and replaced with fresh medium. The
medium was sampled and exchanged at 5 days post-
infection. A third supernatant sample was obtained at
day 7 post infection. Supernatant samples were assayed
for p24 using the HIV-1 p24 ELISA Kit (catalog #
NEK05000, PerkinElmer, Waltham, MA).
Toxicity in cervical explant tissues
MTT assays were performed on the tissues previously
exposed to CuPcS and challenged with HIV to monitor
viability. Single explants were added to individual wells
of a 48-well plate containing 500 μg/mL of MTT in
DMEM in sets of 4 or 8 at each concentration. The ex-
plants were incubated at 37 °C for three hours and then
transferred to 48-well plates containing 1 mL methanol
per well. The plates were incubated at room temperature
overnight in the dark. For analysis, explants were blotted
to remove excess medium and placed in pre-weighed
tubes to determine and record the tissue weight. The ab-
sorbance of three replicates of the MTT supernatant
fluid was determined at 570 nm on a CERES 900 UV
HDi plate reader (Bio-Tek Instruments, Winooski, VT).
Statistical analysis
The effects of CuPcS on toxicity and efficacy were ana-
lyzed using non-linear regression modeling and used to
calculate EC50s/90s and CC50s/90s. A two-tailed t-test
was applied to mean values for percent inhibition in the
cervical explant models, and a one-way analysis of vari-
ance was applied to assess for statistical significance. The
statistical calculations were performed using GraphPad
Prism, Version 6.0d (GraphPad Software, San Diego, CA).
Availability of supporting data
The data supporting the results of this article are in-
cluded within the article and its additional files.
Additional files
Additional file 1: Table S1. Number of Animals by Estrous Phase and
Treatment Group. The number of female mice in each treatment group is
subdivided based on stage of estrus. (DOC 28 kb)
Additional file 2: Table S2. Average Numerical Grade of Leukocytes in
the Vaginal Lamina Propria during Diestrus by Group. The number of
female mice in diestrus is listed according to average leukocyte grade by
treatment group. (DOC 43 kb)
Additional file 3: Table S3. Average Numerical Grade of Leukocytes in
the Vaginal Lamina Propria during Proestrus by Group. The number of
Styczynski et al. Virology Journal  (2015) 12:132 Page 8 of 10
female mice in proestrus is listed according to average leukocyte grade
by treatment group. (DOC 44 kb)
Additional file 4: Table S4. Average Percent Viability of Cervical
Explant Cells with Increasing Concentration of CuPcS. Toxicity as
measured using MTT assay is presented for cervical explant cells over
seven days of exposure to CuPcS. Percent viability was determined as a
function of optical density compared with controls. Concentrations were
tested in quadruplicate. (DOC 25 kb)
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